@article {Ye2020.06.23.20138594, author = {W. Ye and A Olsson-Brown and R. A. Watson and V. T. F. Cheung and R. D. Morgan and I. Nassiri and R. Cooper and C.A. Taylor and O. Brain and R. N. Matin and N. Coupe and M. R. Middleton and M. Coles and J.J. Sacco and M. J. Payne and B. P. Fairfax}, title = {Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanoma}, elocation-id = {2020.06.23.20138594}, year = {2020}, doi = {10.1101/2020.06.23.20138594}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Immune checkpoint blockers (ICBs) activate CD8+ T cells to elicit anti-cancer activity but frequently lead to immune-related adverse events (irAEs). The relationship of irAE with baseline parameters and clinical outcome is unclear. We investigated associations between irAE development, CD8+ T cell receptor diversity and expression and clinical outcome in a non-trial setting.Methods Patients >=18 years old with metastatic melanoma (MM) receiving combination ICB (ipilimumab plus nivolumab {\textendash} cICB, n=60) or single-agent ICB (nivolumab/pembrolizumab {\textendash} sICB, n=78) were prospectively recruited. We retrospectively evaluated the impact of irAEs on survival. This analysis was repeated in an independent cohort of MM patients treated at a separate institution (n=210, cICB:74, sICB:136). We performed RNA sequencing of CD8+ T cells isolated from patients prior to treatment, analysing T cell receptor clonality differential transcript expression according to irAE development.Results 48.6\% of patients experienced treatment-related irAEs within the first 5 cycles of treatment. Development of irAE prior to the 5th cycle of ICB was associated with longer progression-free and overall survival (PFS, OS) in the primary cohort (log-rank test, PFS: P=0.00034; OS: P\<0.0001), replicated in the secondary cohort (OS: P=0.00064). Across cohorts median survival for those patients not experiencing irAE was 14.4 (95\% CI:9.6-19.5) months vs not-reached (95\% CI:28.9 - Inf), P=3.0{\texttimes}10-7. Pre-treatment performance status and neutrophil count, but not BMI, were additional predictors of clinical outcome. Analysis of CD8+ T cells from 128 patients demonstrated irAE development was associated with increased T cell receptor diversity post-treatment (P=4.3{\texttimes}10-5). Development of irAE in sICB recipients was additionally associated with baseline differential expression of 224 transcripts (FDR\<0.1), enriched in pro-inflammatory pathway genes including CYP4F3 and PTGS2.Conclusions Early irAE development post-ICB is strongly associated with favourable survival in MM and increased diversity of peripheral CD8+ T cell receptors after treatment. irAE post-sICB is associated with pre-treatment upregulation of inflammatory pathways, indicating irAE development may reflect baseline immune activation states.Key message Immune-related adverse events (irAEs) commonly occur in patients with metastatic melanoma treated with immune checkpoint blockade (ICB) therapy. In real world setting we find development of early irAEs post-ICB treatment is associated with survival benefit, indicative of a shared mechanism with anti-tumour efficacy. CD8+ T cells from patients who develop irAE show increased receptor diversity, and pre-treatment samples from patients who develop irAE post single-agent anti-PD1 show over-expression of inflammatory pathways, indicating baseline immune state can determine irAE development.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://ega-archive.org/search-results.php?query=EGAS00001004081 Funding StatementThe work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. WY is an Academic Foundation Programme Trainee, RAW is an NIHR Academic Clinical Fellow and recipient of a CRUK predoctoral award (C64881/A26189); BPF is funded by a Wellcome Intermediate Clinical Fellowship (201488/Z/16/Z). ACOB is a MRC Academic Clinical Fellow (Award Ref. MR/N025989/1). VTFAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Oxford data: Oxford Radcliffe Biobank (09/H0606/5+5), OCHRe 16/A019, 18/A064 Liverpool data: HYST study (12/NW/0525) and local audit approval (17-18/40)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequencing data will be made freely available to organizations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research via a data access agreement. Sequence data will be deposited at the European Genome Phenome Archive, which is hosted by the European Bioinformatics Institute and the Centre for Genomic Regulation under accession no. EGAS00001004081. Patient anonymized irAE data will be shared on reasonable request. https://ega-archive.org/search-results.php?query=EGAS00001004081}, URL = {https://www.medrxiv.org/content/early/2020/06/24/2020.06.23.20138594}, eprint = {https://www.medrxiv.org/content/early/2020/06/24/2020.06.23.20138594.full.pdf}, journal = {medRxiv} }